The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Trade War May Ease if China Shifts Manufacturing to US: Jefferies
• 55th GST Council Set to Held on 21 December 
• C2C Advanced Systems IPO GMP Today, Lot Size, Issue Date & Financials
• India to Lead Global Economy and AI: John Chambers
• Nazara Tech and WTFund to Invest in Two Gaming Startups 

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.